Raufman J P, Notar-Francesco V, Raffaniello R D, Straus E W
Division of Digestive Diseases, SUNY-Health Science Center, Brooklyn 11203-2098.
Ann Intern Med. 1993 Apr 1;118(7):488-94. doi: 10.7326/0003-4819-118-7-199304010-00002.
To determine whether the four histamine-2 receptor antagonists currently available for the treatment of acid-peptic disorders in the United States alter serum ethanol levels after moderate alcohol consumption.
Prospective, randomized crossover design comparing the effects of histamine-2 receptor antagonists and no treatment on serum ethanol levels. Each participant served as his own control.
Twenty-five healthy nonalcoholic men (21 to 35 years old); two participants were withdrawn before starting the study.
University medical center.
Cimetidine (400 mg twice daily), famotidine (20 mg twice daily), nizatidine (150 mg twice daily), ranitidine (150 mg twice daily), and no treatment for 7 days. After the last dose of medication, participants ate a standard meal; 1 hour later they drank ethanol (0.3 g/kg body weight in 500 mL of orange juice) over 8 minutes.
Simultaneous measurements of breath and serum (headspace gas chromatography) ethanol were made before and 10, 20, 30, 45, 60, 90, 120, 150, and 180 minutes after ingestion of ethanol.
Peak ethanol levels did not differ (mmol/L; mean +/- SE) after cimetidine (3.0 +/- 0.3), famotidine (2.9 +/- 0.3), nizatidine (2.9 +/- 0.3), ranitidine (3.1 +/- 0.4), and no treatment (2.9 +/- 0.4). Similarly, there was no difference in the area under the curve (mmol/L.h; mean +/- SE) after cimetidine (4.3 +/- 0.5), famotidine (3.8 +/- 0.4), nizatidine (4.2 +/- 0.5), ranitidine (3.9 +/- 0.4), and no treatment (4.0 +/- 0.5).
In healthy nonalcoholic men, the histamine-2 receptor antagonists currently available in the United States do not alter serum ethanol levels following moderate alcohol consumption after an evening meal.
确定美国目前可用于治疗酸相关性疾病的四种组胺-2受体拮抗剂在适度饮酒后是否会改变血清乙醇水平。
前瞻性随机交叉设计,比较组胺-2受体拮抗剂与不治疗对血清乙醇水平的影响。每位参与者均作为自身对照。
25名健康的非酒精性男性(21至35岁);两名参与者在研究开始前退出。
大学医学中心。
西咪替丁(每日两次,每次400毫克)、法莫替丁(每日两次,每次20毫克)、尼扎替丁(每日两次,每次150毫克)、雷尼替丁(每日两次,每次150毫克),每种药物治疗7天,另有7天不进行治疗。在最后一剂药物服用后,参与者进食标准餐;1小时后,他们在8分钟内饮用乙醇(0.3克/千克体重,溶于500毫升橙汁中)。
在摄入乙醇前以及摄入后10、20、30、45、60、90、120、150和180分钟,同时测量呼出气体和血清中的乙醇含量(顶空气相色谱法)。
服用西咪替丁(3.0±0.3)、法莫替丁(2.9±0.3)、尼扎替丁(2.9±0.3)、雷尼替丁(3.1±0.4)以及不进行治疗(2.9±0.4)后,乙醇峰值水平(毫摩尔/升;平均值±标准误)无差异。同样,服用西咪替丁(4.3±0.5)、法莫替丁(3.8±0.4)、尼扎替丁(4.2±0.5)、雷尼替丁(3.9±0.4)以及不进行治疗(4.0±0.5)后,曲线下面积(毫摩尔/升·小时;平均值±标准误)也无差异。
在健康的非酒精性男性中,美国目前可用的组胺-2受体拮抗剂在晚餐后适度饮酒后不会改变血清乙醇水平。